These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8658693)

  • 21. Histologic findings and kidney graft outcome in patients with steroid-resistant rejections before and after OKT3 therapy.
    Niebel W; Metz KA; Albrecht KH; Wagner K; Kribben A; Erhard J; Eigler FW
    Transplant Proc; 1990 Aug; 22(4):1764. PubMed ID: 2117802
    [No Abstract]   [Full Text] [Related]  

  • 22. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies.
    Abramowicz D; Norman DJ; Goldman M; De Pauw L; Kinnaert P; Kahana L; Thistlethwaite JR; Shield CF; Monaco AP; Vanherweghem JL
    Transplant Proc; 1995 Feb; 27(1):852-3. PubMed ID: 7879204
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3.
    Agarwal RK; Ostaszewski ML; Feld LG; Springate JE; Moxey-Mims MM; O'Neil KM
    Transplant Proc; 1993 Apr; 25(2):2143-4. PubMed ID: 8470295
    [No Abstract]   [Full Text] [Related]  

  • 24. The fate of renal allografts treated with OKT3 for steroid-resistant rejection.
    Veronese FV; Gonçalves LF; Vilarinho LL; Macedo VS; Manfro RC
    Transplant Proc; 1999 Nov; 31(7):3016-8. PubMed ID: 10578371
    [No Abstract]   [Full Text] [Related]  

  • 25. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Living related donor kidney transplantation in patients with a positive flow cytometry crossmatch.
    Hong JH; Sadeghian M; Sumrani N; Distant DA; Sommer BG; Norin AJ
    Transplant Proc; 1996 Jun; 28(3):1614-5. PubMed ID: 8658808
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
    Fukuuchi F; Lefrançois N; Chapuis F; Gebuhrer L; Bosshard S; Dubernard JM; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
    [No Abstract]   [Full Text] [Related]  

  • 28. Delayed graft function of cadaveric renal transplants is prevented by diltiazem.
    Carmellini M; Salvadori M; Di Stefano R; Bertoni E; Nicita G; Rosati A; Taddei G; Rindi P; Rizzo G; Mosca F
    Transplant Proc; 1996 Feb; 28(1):80-2. PubMed ID: 8644348
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of HLA matching, type of crossmatch, and immunosuppressive therapy on primary pediatric cadaver renal allograft survival.
    Kerman RH; Sullivan EK; Tejani A
    Transplant Proc; 1995 Feb; 27(1):656-7. PubMed ID: 7879133
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
    Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
    Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of various immunosuppressive regimes in second renal transplants.
    Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
    Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
    [No Abstract]   [Full Text] [Related]  

  • 32. Plasma exchange in highly sensitized patients as induction therapy after renal transplantation.
    Reisaeter AV; Fauchald P; Leivestad T; Holdaas H; Hartmann A; Pfeffer P; Sødal G
    Transplant Proc; 1994 Jun; 26(3):1758. PubMed ID: 8030121
    [No Abstract]   [Full Text] [Related]  

  • 33. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
    Guttmann RD; Flemming C
    Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferation rate of cells in the interstitial infiltrate in acute kidney allograft rejection.
    Olsen S; Hansen HE
    Transplant Proc; 1996 Feb; 28(1):502-3. PubMed ID: 8644329
    [No Abstract]   [Full Text] [Related]  

  • 35. Cyclosporine monotherapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Spanish Monotherapy Study Group.
    Transplant Proc; 1994 Oct; 26(5):2522-4. PubMed ID: 7940775
    [No Abstract]   [Full Text] [Related]  

  • 36. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
    Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
    Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
    [No Abstract]   [Full Text] [Related]  

  • 37. OKT3 induction therapy: influence of duration on rejections and infections.
    Zibari GB; Boykin KN; Thomas JP; Aultman DF; Aradhye SA; McMillan RW; McDonald JC
    Clin Transplant; 1996 Dec; 10(6 Pt 2):614-6. PubMed ID: 8996752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
    Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
    Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
    Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
    [No Abstract]   [Full Text] [Related]  

  • 40. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.